ClinicalTrials.gg
TerminatedNCT00642356Updated Feb 18, 2011Results posted

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

A Phase 4 interventional study of Carbidopa/levodopa/entacapone and Immediate release carbidopa/levodopa in Parkinson's Disease, sponsored by Novartis. Terminated at 21 sites in United States. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-02-18.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Why this study was terminated
slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.

Enrollment
18th of 24
14 · median 46
Started
2008
with 4 others
Phase 4
9 of 24
1 open now
Registered
12th of 24
by date
Lead sponsor
4 of 24
Novartis

Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 18th largest by enrollment, is one of 5 that started in 2008, is one of 9 in phase 4, and was the 12th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carbidopa

Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing carbidopa in Parkinson Disease, or all of them as a file.
02

Study summary

The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on non-motor symptoms of end-of-dose wearing off in persons who have Parkinson's disease.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Idiopathic Parkinson's disease
  • carbidopa/levodopa/entacapone
  • non-motor symptoms
  • motor-symptoms
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be aged 30 to 85 years.
  • Be male or female - female patients must be either not of (defined as post menopausal for at least one year or surgically incapable of bearing children), or must be practicing methods as outlined in the protocol.
  • Have a clinical diagnosis of idiopathic Parkinson's Disease, exhibiting at least 2 of 3 symptoms (rigidity, resting tremor, bradykinesia)
  • Have non-motor symptoms of end of dose wearing off i.e., the presence of at least one non-motor symptom of Parkinson's Disease which improves with the next immediate release (IR) carbidopa/levodopa dose as determined by the Quantitative Wearing-Off Questionnaire 9 and investigator's assessment. At least one non-motor item has to show a severity of at least 2 points (of a maximum of 4) and show an improvement of at least 1 one hour after immediate release (IR) carbidopa/levodopa administration. Also there should not have been a deterioration of 1 point or more in another non-motor item.(all criteria must be fulfilled)
  • Be taking a stable dose of immediate release (IR) carbidopa/levodopa for at least 21 days prior to randomization at an equivalent total daily dose of immediate release (IR) carbidopa/levodopa between 300 to 800 mg. Dosing should be either 3 to 6 times per day.

Exclusion criteria

Exclusion Criteria:

  • Have a previous history of being non-responsive to entacapone or tolcapone treatment or having experienced a serious or severe adverse event(s) which resulted in the discontinuation of treatment from the previous use of entacapone or tolcapone; current treatment with entacapone or tolcapone or discontinued treatment with either therapy or discontinued less than 60 days before randomization;
  • Have a history, signs, or symptoms suggesting a diagnosis of secondary or atypical parkinsonism;
  • Have unstable Parkinson's Disease requiring frequent booster doses;
  • Disabling dyskinesias, indicated by a score of greater than 1 on Unified Parkinson Disease Rating Scale question #32, or a score of greater than 1 on Unified Parkinson Disease Rating Scale question #33;
  • Have a history or current diagnosis of psychotic features according to the investigator;

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Carbidopa/levodopa/entacapone

    Drug: Carbidopa/levodopa/entacapone

  • Active comparator
    Immediate release carbidopa/levodopa

    Drug: Immediate release carbidopa/levodopa

Interventions

  • DrugCarbidopa/levodopa/entacapone

    Drug pages: Carbidopa · Levodopa · Entacapone

    Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.

    Also known as: Stalevo®

  • DrugImmediate release carbidopa/levodopa

    Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.

06

What researchers measure

Primary outcomes

  1. Change From Baseline on the Non-motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)

    The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 4 non-motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the non-motor subscale of the QWOQ-9 is 0 to 16. A higher score indicates greater disability. A negative change score indicates improvement.

    Time frame: Baseline to 15 minutes prior to 2nd dose at Week 8

Secondary outcomes

  1. Change From Baseline on the Motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)

    The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 5 motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the motor subscale of the QWOQ-9 is 0 to 20. A higher score indicates greater disability. A negative change score indicates improvement.

    Time frame: Baseline to 15 minutes prior to 2nd dose at Week 8

07

Results

Posted Jan 11, 2011

Participant flow

Participant flow — Overall Study
MilestoneCarbidopa/Levodopa/EntacaponeImmediate Release Carbidopa/Levodopa
Started77
Completed54
Not completed23
Withdrew: Adverse event10
Withdrew: Protocol violation03
Withdrew: Lack of efficacy10

Outcome measures

PrimaryChange From Baseline on the Non-motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)

The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 4 non-motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the non-motor subscale of the QWOQ-9 is 0 to 16. A higher score indicates greater disability. A negative change score indicates improvement.

Time frame:
Baseline to 15 minutes prior to 2nd dose at Week 8
Reported as:
Mean · Units on a scale
Change From Baseline on the Non-motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)
Units on a scaleCarbidopa/Levodopa/EntacaponeImmediate Release Carbidopa/Levodopa
Change From Baseline on the Non-motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)-0.9 ± 0.90-0.2 ± 2.49
SecondaryChange From Baseline on the Motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)

The QWOQ-9 is a self-rated questionnaire used to assess motor and non-motor symptoms of Parkinson's disease. The 5 motor symptoms are each measured on a five item (0-4) Likert scale, reflecting the severity of the item from "not present" to "very severe". The range of possible score values of the motor subscale of the QWOQ-9 is 0 to 20. A higher score indicates greater disability. A negative change score indicates improvement.

Time frame:
Baseline to 15 minutes prior to 2nd dose at Week 8
Reported as:
Mean · Units on a scale
Change From Baseline on the Motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)
Units on a scaleCarbidopa/Levodopa/EntacaponeImmediate Release Carbidopa/Levodopa
Change From Baseline on the Motor Score of the Quantitative Wearing-Off Questionnaire 9 Item (QWOQ-9)-1.2 ± 2.230.0 ± 2.00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carbidopa/Levodopa/Entacapone—0/7 (0%)4/7 (57.1%)
Immediate Release Carbidopa/Levodopa—0/7 (0%)1/7 (14.3%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventCarbidopa/Levodopa/EntacaponeImmediate Release Carbidopa/Levodopa
NauseaGastrointestinal disorders2/70/7
NervousnessGeneral disorders1/70/7
DyspepsiaGastrointestinal disorders1/70/7
VomitingGastrointestinal disorders1/70/7
FatigueGeneral disorders1/70/7
OedemaGeneral disorders1/70/7
Urinary tract infectionInfections and infestations1/70/7
ExcoriationInjury, poisoning and procedural complications0/71/7
FallInjury, poisoning and procedural complications1/71/7
Head injuryInjury, poisoning and procedural complications0/71/7

Baseline characteristics

Age, Customized
Age, Customized(Participants)Carbidopa/Levodopa/EntacaponeImmediate Release Carbidopa/LevodopaTotal
<=18 years000
Between 18 and 65 years101
>= 65 years6713
Sex: Female, Male
Sex: Female, Male(Participants)Carbidopa/Levodopa/EntacaponeImmediate Release Carbidopa/LevodopaTotal
Female527
Male257
08

Study locations

21 sites
  • Xenoscience, Inc
    Phoenix, Arizona 85004, United States
  • South Coast Health Center
    Aliso Viejo, California 92656, United States
  • University of California
    Irvine, California 92697, United States
  • Coastal Neurological Medical Group, Inc
    La Jolla, California 92037, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Sunrise Clinical Research, Inc
    Hollywood, Florida 33021, United States
  • Charlotte Neurological Services
    Port Charlotte, Florida 33952, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Neurology, Inc
    Columbia, Missouri 65201, United States
  • Dr. John's Mercy Medical Center
    St. Louis, Missouri 63141, United States
  • Creighton U Medical Center, Dept of Neurology
    Omaha, Nebraska 68131, United States
  • Parkinson's Disease & Movement Disorders
    Commack, New York 11725, United States
  • Central New York Research Corporation
    Syracuse, New York 13210, United States
  • Neurological Care of Central NY
    Syracuse, New York 13210, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Neurology Associates
    Monroeville, Pennsylvania 15146, United States
  • University of Pittsburg
    Pittsburg, Pennsylvania 15213, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • University of Texas Medical School
    Houston, Texas 77030, United States
  • Scott & White Hospital
    Temple, Texas 76508, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 25, 2008
Start
Mar 2008
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jan 11, 2011
Last update
Feb 18, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00642356
Lead sponsor
Novartis
First posted
Mar 25, 2008
Start date
Mar 2008
Primary completion
May 2009
Completion
May 2009
Results posted
Jan 11, 2011
Last update
Feb 18, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone

Start the discussion